NewEdge Advisors’s Clovis Oncology, Inc. CLVS Stock Holding History

NewEdge Advisors’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-11,633	Closed	-$56K	–	1129
2020 Q4	$56K	Buy	+11,633	New	+$58.8K	﹤0.01%	954

Other funds holding CLVS

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

NewEdge Advisors's CLVS Position: Q1 2021 in Review

NewEdge Advisors sold out of Clovis Oncology, Inc. (CLVS) in Q1 2021, closing a stake of 11,633 shares — an estimated $56K sold.

NewEdge Advisors first reported a position in CLVS in Q4 2020 and held it in 1 quarter. The position peaked at $56K in Q4 2020. 165 funds tracked by Wall St. Rank hold CLVS as of Q1 2021.

NewEdge Advisors reported no remaining Clovis Oncology, Inc. position as of Q1 2021 after selling out during the quarter.
NewEdge Advisors sold 11,633 Clovis Oncology, Inc. shares in Q1 2021, an estimated $56K.
NewEdge Advisors first reported a position in Clovis Oncology, Inc. in Q4 2020 and held it in 1 quarter.
NewEdge Advisors's Clovis Oncology, Inc. position peaked at $56K in Q4 2020.
165 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q1 2021.

Based on NewEdge Advisors's 13F filing for Q1 2021, filed 26 Apr 2021.